UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of Registrant as Specified in Its Charter)
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s Telephone Number, Including Area Code:
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
| Item 1.02 | Termination of a Material Definitive Agreement |
On November 18, 2021, we entered into Amendment No. 3 to the Global Co-Development and Collaboration Agreement with BeiGene, Ltd. and its wholly owned affiliate BeiGene Switzerland GmbH (collectively, “BeiGene”), dated as of April 8, 2019 and as previously amended on December 24, 2019, and October 5, 2020 (collectively, the “Collaboration Agreement”). Amendment No. 3 provides that the Collaboration Agreement is terminated, subject to survival of certain provisions, that BeiGene hands back rights to technology and know-how received under the Collaboration Agreement, that BeiGene transfers back all regulatory documentation so that we can assume responsibility for the initiation of Phase 1 clinical trials of BA3071, and that we will pay BeiGene mid-single digit royalties and capped milestones, in addition to other standard provisions.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| BioAtla, Inc. | ||||||
| Date: November 19, 2021 | By: | /s/ Richard A. Waldron | ||||
| Names: Richard A. Waldron Title: Chief Financial Officer | ||||||